Skip to search formSkip to main contentSkip to account menu

S 2150

Known as: S-2150 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Diltiazem
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Cardiovascular Pharmacological Characteristics of S-2150: A Novel Dual Blocker of Calcium Channels and α1-Adrenoceptors
2000
2000
Pharmacodynamics of S‐2150, a Simultaneous Calcium‐blocking and α1‐Inhibiting Antihypertensive Drug, in Rats
The in‐vivo pharmacodynamics of S‐2150, a newly developed dual‐blocking type antihypertensive drug, was evaluated following… 
1997
1997
Pharmacological studies on a new antihypertensive agent, S-2150, a benzothiazepine derivative: 3. Hypotensive and antimyocardial-stunning effects in dogs.
The hypotensive and antimyocardial-stunning effects of a new 1,5-benzothiazepine antihypertensive agent, S-2150, were… 
1997
1997
S-2150 の血漿中濃度と降圧効果の速度論的解析
1996
1996
Pharmacological studies on a new antihypertensive agent, S-2150, a benzothiazepine derivative: 2. Hypotensive effects in normotensive and hypertensive rats.
S-2150 is a new 1,5-benzothiazepine derivative possessing both calcium channel-blocking and alpha 1-adrenoceptor-blocking effects… 
1996
1996
Pharmacological studies on a new antihypertensive agent, S-2150, a benzothiazepine derivative: 1. Antinecrotic and antiarrhythmic effects in reperfused rat hearts.
S-2150 is a new 1,5-benzothiazepine derivative that inhibits [3H]diltiazem and [3H]WB4101 bindings to the membrane of rat tissue… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)